AFM Completes Investigation into Exercising of Options by Crucell Management
01 avr. 2005 08h58 HE
|
Crucell N.V.
LEIDEN, Netherlands, April 1, 2005 (PRIMEZONE) -- The Netherlands Authority for the Financial Markets (AFM) has notified Crucell that its investigation into the exercise of options and the subsequent...
Crucell N.V.: Staf Van Reet to lead Galapagos Corporate Development
31 mars 2005 05h06 HE
|
Crucell N.V.
LEIDEN, The Netherlands, March 31, 2005 (PRIMEZONE) -- Galapagos, a genomics-based drug discovery company, announces that it has appointed Staf Van Reet as VP Corporate Development. Dr. Van Reet will...
Crucell Announces PER.C6 Licensing Agreement with Vascular Biogenics
30 mars 2005 01h31 HE
|
Crucell N.V.
LEIDEN, The Netherlands, March 30, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(R) research license agreement...
Crucell and DSM Announce PER.C6 Licensing Agreement with Mitsubishi Pharma for Protein Production
23 mars 2005 02h06 HE
|
Crucell N.V.
LEIDEN, The Netherlands, March 23, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that DSM...
Crucell Signs Commercial PER.C6 License Agreement with SingVax for Vaccines against Japanese Encephalitis
22 mars 2005 08h18 HE
|
Crucell N.V.
LEIDEN, Netherlands, March 22, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced the signing of a commercial PER.C6(R) license agreement with...
Crucell Secures Exclusive Patent License from NIH to Commercialize Ebola Vaccines
18 mars 2005 02h07 HE
|
Crucell N.V.
LEIDEN, Netherlands, March 18, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has obtained an exclusive license to certain patents...
Crucell and NIH extend Ebola Vaccine Agreement
17 mars 2005 02h07 HE
|
Crucell N.V.
LEIDEN, The Netherlands, March 17, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has extended its Cooperative Research and...
Crucell and DSM Announce PER.C6 Licensing Agreement with JCR Pharmaceuticals for Protein Production
10 mars 2005 02h11 HE
|
Crucell N.V.
LEIDEN, The Netherlands, March 10, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they...
Crucell N.V.: Galapagos is Considering a Stock Exchange Listing
09 mars 2005 03h36 HE
|
Crucell N.V.
LEIDEN, The Netherlands, March 9, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) announced today that Galapagos Genomics N.V. is considering a Euronext...
Galapagos Considering a Stock Exchange Listing
09 mars 2005 03h18 HE
|
Crucell N.V.
LEIDEN, The Netherlands, March 9, 2005 (PRIMEZONE) -- Galapagos Genomics NV, a genomics-based drug discovery company, announces that it is considering a Euronext stock exchange listing in 2005. The...